16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)V. Moreno,I. Braña,J.M. Sepulveda Sanchez,M. Vieito Villar,T. Hernández Guerrero, B. Doger,O. Saavedra,A. Pinto,C. Carlo Stella,A. Italiano,J-M. Michot, G. Musuraca,R. Sarmiento,J. De Alvaro, M. Zuraek, T. Sánchez-Pérez, I. Aronchik, E. Filvaroff,B. Hanna, Z. NikolovaAnnals of Oncology（2020）引用 3|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
